Diagnosis and treatment of plasmodium vivax malaria

American Journal of Tropical Medicine and Hygiene

Volumn 95, Issue , 2016, Pages 35-51

  Baird, J Kevin ^a,b   Valecha, Neena ^c   Duparc, Stephan ^d   White, Nicholas J ^b,e   Price, Ric N ^b,f  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^d Medicines for Malaria Venture   (Switzerland)

^e MAHIDOL UNIVERSITY   (Thailand)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; BULAQUINE; METHYLENE BLUE; PRIMAQUINE; TAFENOQUINE; TINIDAZOLE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL (TOPIC); CYTOLOGY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; GENETIC ANALYSIS; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; IN VIVO STUDY; LABORATORY TEST; LIVER; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MALARIA RAPID TEST; MICROSCOPY; NONHUMAN; PARASITEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RELAPSE; SCREENING TEST; SEROLOGY; TREATMENT INDICATION; DRUG EFFECTS; DRUG RESISTANCE; MALARIA, VIVAX; ABNORMAL URINE COMPOSITION; ANEMIA; CYTODIAGNOSIS; EVIDENCE BASED PRACTICE; HEMOGLOBINURIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTRAVASCULAR HEMOLYSIS; JAUNDICE; KIDNEY FAILURE; PLASMODIUM (LIFE CYCLE STAGE); PRACTICE GUIDELINE; PSYCHOSIS; RECURRENCE RISK; RISK REDUCTION; SERODIAGNOSIS; VULNERABLE POPULATION;

ANTIMALARIALS; DRUG RESISTANCE; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX;

EID: 85012919614     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.16-0171     Document Type: Article

References (142)

1. World Health Organization, 2015. Guidelines for the Treatment of Malaria. 3rd edition. Geneva, Switzerland: WHO.
2. http://www.who.int/tdr/publications/microscopy-detec-ident-quantif/en/. Accessed October 20, 2015.
3. World Health Organization, 2009. Malaria Microscopy Quality Assurance Manual. Manila, Philippines: WHO, Western Pacific Regional Office.
4. World Health Organization, 2010. Basic Malaria Microscopy. 2nd edition. Geneva, Switzerland: WHO.
5. Greenwood BM, Armstrong JR, 1991. Comparison of two simple methods for determining parasite density. Trans R Soc Trop Med Hyg 85: 186-188.
6. Wilcox A, 1960. Manual for the Microscopical Diagnosis of Malaria in Man. Washington, DC: U.S. Government Printing Office.
7. Bruce-Chwatt LJ, 1980. Essential Malariology. London, United Kingdom: William Heinemann Medical Books Ltd.
8. World Health Organization, 2010. Parasitological Confirmation of Malaria Diagnosis: Report of a WHO Technical Consultation, Geneva, 6-8 October 2009. Geneva, Switzerland: WHO.
9. World Health Organization, 2009. How to Use a Rapid Diagnostic Test (RDT): A Guide for Training at a Village and Clinic Level. Geneva, Switzerland: WHO.
10. World Health Organization, 2012. Malaria Rapid Diagnostic Test Performance: Summary of Results of WHO Product Testing of Malaria RDTs, Round 1-4 (2008-2012). Geneva, Switzerland: WHO. 2012.
11. Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S, Garner P, Takwoingi Y, 2014. Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries. Cochrane Database Syst Rev 12: CD011431.
12. Okell LC, Ghani AC, Lyons E, Drakeley CJ, 2009. Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis 200: 1509-1517.
13. Cheng Q, Cunningham J, Gatton ML, 2015. Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis 9: e3413.
14. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, Suangkanarat P, Jeeyapant A, Vihokhern B, Hue DV, Dong LT, Nugyen TU, Lubell Y, von Seidlein L, Dhorda M, Pomnarate C, Snounou G, Malleret B, Renia L, Keereecharoen L, Singhasivanon P, Sirithiranont P, Chalk J, Nguon C, Hien TT, Day N, White NJ, Dondorp A, Nosten F, 2015. The epidemiology of subclinical malaria in southeast Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. Malar J 14: 381.
15. Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, Christophel EM, Bjorge S, Thomson A, Kheng S, Chea N, Yok S, Top S, Ros S, Sophal U, Thompson MM, Mellor S, Ariey F, Witkowski B, Yeang C, Yeung S, Duong S, Newman RD, Menard D, 2012. Focused screening and treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. PLoS One 7: e45797.
16. Sounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN, 1993. High sensitivity of detection of human malaria parasites by use of the nested polymerase chain reaction. Mol Biochem Parasitol 61: 315-320.
17. Hopkins H, Gonazalez IJ, Polley SD, Angutoko P, Ategeka J, Asiimwe C, Agaba C, Kyabayinze DJ, Sutherland CJ, Perkins MD, Bell D, 2013. Highly sensitive detection of malaria parasitemia in a malaria endemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. J Infect Dis 208: 645-652.
18. Polley SD, Gonzalez IJ, Mohamed D, Daly R, Bowers K, Watson J, Mewse E, Armstrong M, Gray C, Perkins MD, Bell D, Kanda H, Tomita N, Kubota Y, Mori Y, Chiodini PL, Sutherland CJ, 2013. Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria. J Infect Dis 208: 637-644.
19. Lu F, Gao Q, Zhou H, Cao J, Wang W, Lim CS, Na S, Tsuboi T, Han ET, 2012. Molecular test for vivax malaria with loopmediated isothermal amplification method in central China. Parasitol Res 110: 2439-2444.
20. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI, 2012. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical modelbased map. PLoS Med 9: e1001339.
21. Cappellini MD, Fiorelli G, 2008. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371: 64-74.
22. Ardern JC, Edwards N, Hyde K, Jardine-Wilkinson C, Cinkotai KI, Power DM, MacIver JE, 1988. A proposal for further standardization of red blood cell glucose-6-phosphate dehydrogenase determinations. Clin Lab Haematol 10: 409-416.
23. Modiano G, Battistuzzi G, Esan GJ, Testa U, Luzzatto L, 1979. Genetic heterogeneity of "normal" erythrocyte glucose-6-phosphate dehydrogenase: an isoelectrophoretic polymorphism. Proc Natl Acad Sci USA 76: 852-856.
24. Satyagraha AW, Sadhewa A, Baramuli V, Elvira R, Ridenour C, Elyazar I, Noviyanti R, Coutrier FN, Harahap AR, Baird JK, 2015. G6PD deficiency at Sumba in eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing vivax malaria. PLoS Negl Trop Dis 9: e0003602.
25. Aminwero CE, Olatunji PO, 2007. Re-evaluation of methaemoglobin reduction as a screening procedure for glucose-6-phosphate dehydrogenase (G6PD). Afr Med Med Sci 36: 177-181.
26. Sanpavat S, Nuchprayoon I, Kittikalayawong A, Ungbumnet W, 2001. The value of methemoglobin reduction test as a screening test for neonatal glucose-6-phosphate dehydrogenase deficiency. J Med Assoc Thai 84 (Suppl 1): S91-S98.
27. Peters AL, Van Noorden CJ, 2009. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem 57: 1003-1011.
28. Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, Wellems TE, Fairhurst RM, 2012. A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. Sci Rep 2: 299.
29. Benmansour I, Moradkhani K, Moumni I, Wajcman H, Hafsia R, Ghanem A, Abbes S, Prehu C, 2013. Two new class III G6PD variants [G6PD Tunis (c.920AC: p.307GlnPro) and G6PD Nefza (c.968TC: p.323 LeuPro] and overview of the spectrum of mutations in Tunisia. Blood Cells Mol Dis 50: 110-114.
30. Sirdah M, Reading NS, Vankayalapati H, Perkins SL, Shubair ME, Aboud L, Roper D, Prchal JT, 2012. Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Gaza Strip Palestinians. Blood Cells Mol Dis 49: 152-158.
31. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW, 2015. Non-inferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test versus the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res 165: 677-688.
32. Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, Oyong D, Subekti D, Rozi IE, Domingo GJ, Harahap AR, Baird JK, 2016. Assessment of point-of-care diagnostics for G6PD deficiency in malaria endemic rural eastern Indonesia. PLoS Negl Trop Dis 10: e0004457.
33. World Health Organization, 2015. http://www.who.int/malaria/mpac/mpac-march2015-erg-g6pd.pdf. Accessed October 20 and 22, 2015.
34. Kuwahata M, Wijesinghe R, Ho MF, Pelecanos A, Bobogare A, Landry L, Bugora H, Vallely A, McCarthy J, 2010. Population screening for glucose-6-phosphate dehydrogenase deficiencies in Isabel Province, Solomon Islands, using a modified enzyme assay on filter paper dried bloodspots. Malar J 9: 223.
35. De Niz M, Eziefula AC, Othieno L, Mbabazi E, Nabukeera D, Ssemmondo E, Gonahasa S, Tumwebaze P, Diliberto D, Maiteki-Sebuguzi C, Staedke SG, Drakeley C, 2013. Tools for mass screening of G6PD deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in Uganda. Malar J 12: 210.
36. Baird JK, Hoffman SL, 2003. Primaquine for the prevention of malaria in travelers. Clin Infect Dis 37: 1659-1667.
37. Ohrt C, Purnomo Sutamihardja MA, Tang D, Kain KC, 2002. Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. J Infect Dis 186: 540-546.
38. Baird JK, Maguire JD, Price RN, 2012. Diagnosis and treatment of Plasmodium vivax malaria. Adv Parasitol 80: 203-270.
39. World Health Organization, 2010. Guidelines for the Treatment of Malaria. 2nd edition. Geneva, Switzerland: WHO.
40. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M, 1982. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. Plasmodium vivax. Am J Trop Med Hyg 31: 10-13.
41. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuan S, White NJ, 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 1680-1685.
42. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 46: 3947-3953.
43. Maguire JD, Krisin Marwoto H, Richie TL, Fryauff DJ, Baird JK, 2006. Mefloquine is highly efficacious against chloroquineresistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 42: 1067-1072.
44. Lacy MD, Maguire JD, Barcus MJ, Ling J, Bangs MJ, Gramzinski R, Basri H, Sismadi P, Miller GB, Chulay JD, Fryauff DJ, Hoffman SL, Baird JK, 2002. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 35: e92-e95.
45. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL, 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171: 1678-1682.
46. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757-765.
47. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM, 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545-2557.
48. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN, 2010. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10: 405-416.
49. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, 2011. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 6: e14501.
50. Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D, 2013. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev 10: CD008492.
51. World Health Organization, 2012. World Malaria Report 2012. Geneva, Switzerland: WHO.
52. Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti Elyazar I, Bangs MJ, Maguire JD, Baird JK, 2007. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 77: 984-991.
53. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN, 2008. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5: e128.
54. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I, 2008. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 5: e127.
55. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V, 2009. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am J Trop Med Hyg 80: 194-198.
56. Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes BL, Mourao MP, Lacerda MV, Alecrim MD, 2010. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis 16: 1611-1614.
57. Andrade BB, Reis-Filho A, Souza-Neto SM, Clarencio J, Camargo LM, Barral A, Barral-Netto M, 2010. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J 9: 13.
58. Price L, Planche T, Rayner C, Krishna S, 2007. Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans R Soc Trop Med Hyg 101: 655-659.
59. Anstey NM, Russell B, Yeo TW, Price RN, 2009. The pathophysiology of vivax malaria. Trends Parasitol 25: 220-227.
60. Tan LK, Yacoub S, Scott S, Bhagani S, Jacobs M, 2008. Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis 8: 449-454.
61. Lampah DA, Yeo TW, Hardianto SO, Tjitra E, Kenangalem E, Sugiarto P, Price RN, Anstey NM, 2011. Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia. PLoS Negl Trop Dis 5: e1032.
62. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN, 2012. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 80: 151-201.
63. Dondorp A, Nosten F, Stepniewska K, Day N, White N, South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group, 2005. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717-725.
64. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ; AQUAMAT group, 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 1647-1657.
65. Rieckmann KH, Davis DR, Hutton DC, 1989. Plasmodium vivax resistance to chloroquine? Lancet 2: 1183-1184.
66. Baird JK, Basri H, Purnomo, Bangs MJ, Subianto B, Patchen LC, Hoffman SL, 1991. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 44: 547-552.
67. Price RN, Auburn S, Marfurt J, Cheng Q, 2012. Phenotypic and genotypic characterization of drug-resistant Plasmodium vivax. Trends Parasitol 28: 522-529.
68. Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, Sekartuti, Fryauff DJ, Baird JK, 2003. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 68: 416-420.
69. Ratcliff A, Siswantoro H, Kenangalem E,Wuwung M, Brockman A, Edstein MD, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, 2007. Therapeutic response of multidrugresistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 101: 351-359.
70. Baird JK, 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075-4083.
71. Price RN, Douglas NM, Anstey NM, 2009. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 22: 430-435.
72. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ, 2014. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 10: 982-991.
73. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F, Looareesuwan S, White NJ, Snounou G, 2005. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J 4: 20.
74. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q, 2007. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 195: 934-941.
75. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP, Felger I, 2009. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 199: 1074-1080.
76. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TM, Mueller I, 2011. Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother 55: 4479-4481.
77. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day NP, Anderson TJ, White NJ, 2007. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927-933.
78. White NJ, 2011. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10: 297.
79. Udomsangpetch R, Somsri S, Panichakul T, Chotivanich K, Sirichaisinthop J, Yang Z, Cui L, Sattabongkot J, 2007. Shortterm in vitro culture of field isolates of Plasmodium vivax using umbilical cord blood. Parasitol Int 56: 65-69.
80. Golenda CF, Li J, Rosenberg R, 1997. Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proc Natl Acad Sci USA 94: 6786-6791.
81. Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer WH, Na-Bangchang K, 2006. Clinical-parasito logical response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Trans R Soc Trop Med Hyg 100: 410-418.
82. Russell BM, Udomsangpetch R, Rieckmann KH, Kotecka BM, Coleman RE, Sattabongkot J, 2003. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob Agents Chemother 47: 170-173.
83. Chotivanich K, Udomsangpetch R, Chierakul W, Newton PN, Ruangveerayuth R, Pukrittayakamee S, Looareesuwan S, White NJ, 2004. In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am J Trop Med Hyg 70: 395-397.
84. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Let-Uthai U, Anstey NM, Titra E, Nosten F, Cheng Q, Price RN, 2007. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One 2: e1089.
85. Hasugian AR, Tjitra E, Ratcliff A, Siswantoro H, Kenangalem E, Wuwung RM, Purba HL, Piera KA, Chalfien F, Marfurt J, Penttinen PM, Russell B, Anstey NM, Price RN, 2009. In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother 53: 1094-1099.
86. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, Prasetyorini B, Kenangalem E, Piera KA, Lek-Uthai U, Anstey NM, Titra E, Nosten F, Cheng Q, Price RN, 2008. Amplification of pvmdr1 associated with multidrugresistant Plasmodium vivax. J Infect Dis 198: 1558-1564.
87. Chotivanich K, Sattabongkot J, Choi YK, Park JS, Sritabal J, Lim CS, Udomsangpetch R, White NJ, Lee WJ, 2009. Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg 80: 902-904.
88. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, Skinner-Adams TS, Nosten F, Gardiner DL, Boonma P, Piera KA, Andrews KT, Machunter B, McCarthy JS, Anstey NM, Price RN, Russell B, 2008. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother 52: 2435-2441.
89. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Fairlie DP, Tjitra E, Anstey NM, Andrews KT, Price RN, 2011. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother 55: 961-966.
90. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Machunter B, Tjitra E, Anstey NM, Price RN, 2011. Ex vivo drug susceptibility of ferroquine against chloroquineresistant isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother 55: 4461-4464.
91. Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, Anstey NM, Russell B, 2010. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother 54: 5146-5150.
92. Marfurt J, Chalfein F, Prayoga P, Wabiser F, Wirjanata G, Sebayang B, Piera KA, Wittlin S, Haynes RK, Mohrle JJ, Anstey NM, Kenangalem E, Price RN, 2012. Artemisininbased combination therapy against P. vivax: comparative ex vivo activity of next-generation endoperoxides in multidrug resistant field isolates. Antimicrob Agents Chemother 56: 5258-5263.
93. Druilhe P, Brasseur P, Blanc C, Makler M, 2007. Improved assessment of Plasmodium vivax response to antimalarial drugs by a colorimetric double-site Plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay. Antimicrob Agents Chemother 51: 2112-2116.
94. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, Fidock DA, Su X, Collins WE, McCutchan TF, Wooton JC, Wellems TE, 2001. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J Infect Dis 183: 1653-1661.
95. Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, Menard D, 2008. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother 52: 4233-4240.
96. Fernandez-Becerra C, Pinazo MJ, Gonzalez A, Alonso PL, del Portillo HA, Gascon J, 2009. Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar J 8: 55.
97. Marfurt J, de Monbrison F, Brega S, Barbollat L, Muller I, Sie A, Goroti M, Reeder JC, Beck HP, Picot S, Genton B, 2008. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J Infect Dis 198: 409-417.
98. Sa JM, Nomura T, Neves J, Baird JK, Wellems TE, del Portillo HA, 2005. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol 109: 256-259.
99. Kim YK, Kim C, Park I, Kim HY, Choi JY, Kim JM, 2011. Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis. Am J Trop Med Hyg 84: 532-534.
100. Dern RJ, Weinstein IM, Leroy GV, Talmage DW, Alving AS, 1954. The hemolytic effect of primaquine. I. The localization of the drug-induced hemolytic defect in primaquine-sensitive individuals. J Lab Clin Med 43: 303-309.
101. Beutler E, 1959. The hemolytic effect of primaquine and related compounds: a review. Blood 14: 103-139.
102. Clyde DF, McCarthy VC, 1977. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg 26: 562-563.
103. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, 2006. Primaquine: report from CDC expert meeting in malaria chemoprophylaxis I. Am J Trop Med Hyg 75: 402-415.
104. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11: 280.
105. Baird JK, 2009. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 22: 508-534.
106. Galappaththy GN, Omari AA, Tharyan P, 2007. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev CD004389.
107. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK, 2013. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 57: 1128-1135.
108. Nelwan EJ, Ekawati LL, Tjahono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK, 2015. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med 13: 294.
109. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, Puangsa-art S, Thanyavanich N, Maneeboonyang W, Day NP, Singhasivanon P, 2010. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J 9: 308.
110. Maneeboonyang WLS, Puangsa-Art S, Yimsamran S, Thanyavanich N, Wuthisen P, Prommongkol S, Chaimongkul W, Rukmanee P, Rukmanee N, Chavez IF, Buchachart K, Krudsood S, Singhasivanon P, 2011. Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health 42: 9-18.
111. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M, 2004. Compliance with 14-day primaquine therapy for radical cure of vivax malaria-a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 98: 168-173.
112. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S, 2008. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 78: 736-740.
113. Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK, 2014. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J 13: 488.
114. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369: 1381-1382.
115. Recht R, Ashley E, White N, 2014. Safety of 8-Aminoquinoline Antimalarial Medicines. Geneva, Switzerland: World Health Organization.
116. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, Siqueiera AM, Ferreira LC, Araujo JR, Mourao MP, Ferrer M, Castillo P, Martin-Jaular L, Fernandez-Becerra C, del Portillo H, Ordi J, Alonso PL, Bassat Q, 2012. Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax: to what extent does this parasite kill? Clin Infect Dis 55: e67-e74.
117. Monteiro WM, Moura-Neto JP, Recht J, Bassat Q, Lacerda MV, 2016. Fatal primaquine-induced hemolysis in a patient with Plasmodium vivax malaria and G6PD A(-) variant in the Brazilian Amazon. Clin Infect Dis 62: 1188.
118. Grietens KPSV, Erhart A, Ribera JM, Toomer E, Tenorio A, Montalvo TG, Rodriguez H, Cuentas AL, D'Alessandro U, Gamboa D, 2010. Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. Am J Trop Med Hyg 82: 1017-1023.
119. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE, 1960. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. A preliminary report. Bull World Health Organ 22: 621-631.
120. Burgess RW, Bray RS, 1961. The effect of a single dose of primaquine on the gametocytes and sporogony of Laverania (=Plasmodium) falciparum. Bull World Health Organ 24: 451-456.
121. Rieckmann KH, McNamara JV, Kass L, Powell RD, 1969. Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Mil Med 134: 802-819.
122. Clyde DF, 1981. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 59: 128-134.
123. Baird JK, Surjadjaja C, 2011. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol 27: 11-16.
124. Kheng S, Muth S, Taylor WR, Tops N, Kosal K, Sothea K, Souy P, Kim S, Char CM, Vanna C, Ly P, Ringwald P, Khieu V, Kerleguer A, Tor P, Baird JK, Bjorge S, Menard D, Christophel E, 2015. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with G6PD deficiency. BMC Med 13: 203.
125. Wang J, Xiao QZ, Chen YM, Yi S, Liu D, Liu YH, Zhang CM, Wei XF, Zhou YQ, Zhong XM, Zhao CY, Xiong F, Wei XC, Xu XM, 2014. DNA hypermethylation and X chromosome inactivation are major determinants of phenotypic variation in women heterozygous for G6PD mutations. Blood Cells Mol Dis 53: 241-245.
126. Baird JK, 2011. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 55: 1827-1830.
127. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN, 2011. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612-620.
128. Baird JK, 2011. Radical cure: the case for anti-relapse therapy against all the malarias. Clin Infect Dis 52: 621-623.
129. White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, Jeeyapant A, Jain JP, Lefevre G, Li R, Magnusson B, Diagana TT, Leong FJ, 2014. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med 371: 403-410.
130. Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price RN, Avery VM, Angulo-Barturen I, Jimenez-Diaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK, 2013. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med 5: 177ra37.
131. Wells TN, Burrows JN, Baird JK, 2010. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol 26: 145-151.
132. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Cheunhom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L, 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383: 1049-1058.
133. Baird JK, 2012. Reinventing primaquine for endemic malaria. Expert Opin Emerg Drugs 17: 439-444.
134. Müller O, Mockenhaupt FP, Marks B, Meissner P, Coulibaly B, Kuhnert R, Buchner H, Schirmer RH, Walter-Sack I, Sie A, Mansmann U, 2013. Haemolysis risk in methylene blue treatment of G6PD-sufficient and G6PD-deficient West-African children with uncomplicated falciparum malaria: a synopsis of four RCTs. Pharmacoepidemiol Drug Saf 22: 376-385.
135. Adak T, Valecha N, Sharma VP, 2001. Plasmodium vivax polymorphism in a clinical drug trial. Clin Diagn Lab Immunol 8: 891-894.
136. Valecha N, Adak T, Bagga AK, Asthana OP, Srivastava JS, Joshi H, Sharma VP, 2001. Comparative antirelapse efficacy of bulaquine and primaquine in double blind clinical trial. Curr Sci 80: 561-563.
137. Krudsood S, Wilairatana P, Tangpukdee N, Chalermrut K, Srivilairit S, Thanachartwet V, Muangnoicharoen S, Luplertlop N, Brittenham GM, Looareesuwan S, 2006. Safety and tolerability elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmodium vivax malaria in Thailand. Korean J Parasitol 44: 221-228.
138. Macareo L, Lwin KM, Cheah PY, Yuentrakul P, Miller RS, Nosten F, 2013. Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse. Malar J 12: 173.
139. Meister S, Plouffe DM, Kuhen KL, Bonamy GMC, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MCS, McNamara CW, Fidock DA, Nagle A, Nam T, Richmond W, Roland J, Rottman M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA, 2011. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334: 1372-1377.
140. Dembele L, Gego A, Zeeman AM, Fraetich JF, Silvie O, Rametti A, Le Grand R, Dereuddre-Bosquet N, Sauerwein R, van Gemert GJ, Vaillant JC, Thomas AW, Snounou G, Kocken CHM, Mazier D, 2011. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One 6: e18162.
141. Dembele L, Franetich JF, Lorthiois A, Gego A, Zeeman AM, Kocken CH, Le Grand R, Dereuddre-Bosquet N, van Gemert GJ, Sauerwein R, Vaillant JC, Hannoun L, Fuchter MJ, Diagana TT, Malmquist NA, Scherf A, Snounou G, Mazier D, 2014. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat Med 20: 307-312.
142. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D, 2012. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med 9: e1001169.